Switzerland · 
Who invested in NBE-Therapeutics?
NBE-Therapeutics's investors include Boehringer Ingelheim Venture Fund and Novo Holdings.
201520162017201820192020
$3.1MSeries A$22MSeries CSwitzerland · Series C startup
Who invested in NBE-Therapeutics
Funding summaryUpdated 26 Oct 2026
$25Mraised across 2 rounds since 2015, from 2 sources
$3.1MSeries A$22MSeries C
- Latest round
- Series C, $22MJan 2020
- Step-upi
- 7.1×
- Investors
- 2
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Series A, $3.1M Mar 2015
- Biggest round
- $22M Series C · Jan 2020
- Between rounds
- 4.8 years from the last two
The rounds
- Jan 2020
- Mar 2015
Founders and team
From NBE-Therapeutics's own website: 3 on the team.
- Andy BrossChief Financial Officer
- Dr. Carl DeutschChief Scientific Officer
- Dr. Olof PrauseChief Operating Officer
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Boehringer Ingelheim Venture FundCorporate VC2rounds
Missing a round, or an investor who was in one? Tell us.
Quick answers about NBE-Therapeutics
How much has NBE-Therapeutics raised?
NBE-Therapeutics has raised $25M across 2 rounds since 2015.
When did NBE-Therapeutics last raise?
NBE-Therapeutics's most recent round was a Series C of $22M in Jan 2020.
What was NBE-Therapeutics's biggest round?
Its most recent round, $22M in Jan 2020, is also its largest on record.
Who backed NBE-Therapeutics first?
NBE-Therapeutics's first round on record, in Mar 2015, was backed by Boehringer Ingelheim Venture Fund.
What stage is NBE-Therapeutics at?
NBE-Therapeutics's latest named round is a Series C, in Jan 2020.
Where is NBE-Therapeutics based?
NBE-Therapeutics is based in Switzerland.
Companies like NBE-Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.